Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

Sarepta Therapeutics is undergoing a major restructuring, cutting approximately 36% of its workforce (around 500 employees) and pausing several drug programs, targeting over $400 million in annual cost savings by 2026. This strategic move addresses significant setbacks with its key Duchenne gene therapy, Elevidys, including patient deaths, sales restrictions for non-ambulatory patients, and an FDA black box warning, which contributed to an 80%+ share price decline this year. Despite these challenges, Sarepta, which became profitable in 2024, aims to maintain financial viability by focusing on ambulatory Elevidys sales, its existing exon-skipping drugs, and new RNA-based therapies, a strategy that led to an after-hours stock price increase.

Analysis

Sarepta Therapeutics is executing a significant corporate restructuring, cutting its workforce by 36% and halting several research programs to achieve over $400 million in annual cost savings by 2026. This decisive action is a direct response to severe setbacks for its cornerstone Duchenne gene therapy, Elevidys, which have precipitated an over 80% decline in its share price this year. The core issues stem from two patient deaths, which led the company to halt sales to non-ambulatory patients and resulted in the FDA imposing a black box warning for liver injury risk. This has materially impacted financials, with Elevidys sales falling from $375 million in Q1 to $282 million in Q2 and the company suspending its financial forecasts. Management is now re-basing the company's outlook on a more conservative and de-risked model, projecting a minimum of $500 million in annual revenue from Elevidys in the ambulatory patient population, supplemented by approximately $900 million per year from its existing exon-skipping drugs. The restructuring also involves a strategic pivot in R&D, concentrating resources on its RNA-based medicine collaboration with Arrowhead Pharmaceuticals, which the company highlights as having significant near-term potential. The after-hours share price increase following the announcement suggests that investors may view this painful but necessary realignment as a credible path to preserving long-term viability and managing its $1 billion debt maturity in 2027.

Key Decisions for Investors

• Re-evaluate Sarepta's valuation based on its new, more conservative revenue profile of approximately $1.4 billion from its commercial Duchenne portfolio, assessing if this can support its cost structure and service its $1 billion in senior notes due 2027.
• Closely monitor all communications with the FDA regarding Elevidys, as the unresolved status for non-ambulatory patients represents a major uncertainty and a potential catalyst for significant share price movement.
• Track clinical progress within the prioritized RNA-based programs developed with Arrowhead Pharmaceuticals, as success in this pipeline is now critical to the company's long-term growth narrative and justifying a valuation beyond its current commercial assets.